Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis: A scientific meeting
To learn about the exciting new directions in drug therapy for osteoporosis and other bone diseases, media are invited to attend Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis, a two-day meeting focusing on the current and future status of bone-building anabolic skeletal agents for osteoporosis treatment. This ground-breaking meeting is cosponsored by the American Society for Bone and Mineral Research and the National Institutes of Health.
The first of the therapeutic skeletal anabolic agents, parathyroid hormone (PTH), has now been on the market for more than a year. The success of this drug, coupled with recent advances in the understanding of bone formation and identification of new potential signaling molecules and targets for anabolic skeletal agents, has revolutionized the field of osteoporosis therapy. This means that clinicians and researchers can now approach osteoporosis therapeutically in two completely different ways: by slowing bone loss (the old way) and by stimulating new bone formation (the new, anabolic way).
Speakers at the May 24-25 meeting include world-renowned scientists Thomas Clemens, Ph.D., Susan Greenspan, M.D., Thomas Einhorn, M.D., Mark Johnson, Ph.D., Sundeep Khosla, M.D., and Stavros Manolagas, M.D., Ph.D.
This scientific meeting is also co-sponsored by The American Academy of Orthopaedic Surgeons, The Endocrine Society, The International Society for Clinical Densitometry, The National Institute of Diabetes and Digestive and Kidney Diseases, The National Institute on Aging, The National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Child Health and Human Development, The National Institute of Dental and Craniofacial Research, The National Osteoporosis Foundation and The Osteogenesis Imperfecta Foundation.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.